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AbstrACt
Introduction Rheumatoid arthritis (RA) and ankylosing 
spondylitis (AS) are chronic, systemic, inflammatory 
diseases, primarily in the musculoskeletal system. Pain 
and fatigue are key symptoms of RA and AS. Treatment 
presents a clinical challenge for several reasons, including 
the progressive nature of the diseases and the involvement 
of multiple pain mechanisms. Moreover, side effects of 
pain treatment pose an implicit risk. Currently, no well-
controlled studies have investigated how medical cannabis 
affects pain and cognitive functions in RA and AS. The 
present study aims to evaluate the efficacy and safety of 
medical cannabis in the treatment of persistent pain in 
patients with RA and AS with low disease activity.
Methods and analysis A double-blinded, randomised, 
placebo-controlled study of cannabidiol (CBD), followed by 
an open label add-on of tetrahydrocannabinol (THC) with 
collection of clinical data and biological materials in RA 
and AS patients treated in routine care. The oral treatment 
with CBD in the experimental group is compared with 
placebo in a control group for 12 weeks, followed by an 
observational 12-week period with an open label add-
on of THC in the primary CBD non-responders. Disease 
characteristics, psychological parameters, demographics, 
comorbidities, lifestyle factors, blood samples and serious 
adverse events are collected at baseline, after 12 and 24 
weeks of treatment, and at a follow-up visit at 36 weeks. 
Data will be analysed in accordance with a predefined 
statistical analysis plan.
Ethics and dissemination The Danish Ethics Committee 
(S-20170217), the Danish Medicines Agency (S-
2018010018) and the Danish Data Protection Agency 
approved the protocol. The project is registered in the 
European Clinical Trials Database (EudraCT 2017-004226-
15). All participants will give written informed consent 
to participate prior to any study-related procedures. The 
results will be presented at international conferences and 
published in peer-reviewed journals.
IntroduCtIon
The treatment of rheumatoid arthritis (RA) 
and ankylosing spondylitis (AS) has improved 
significantly over the last three decades.1–3 
Chronic pain and fatigue are symptoms 
typical of these major inflammatory rheu-
matic disorders.4–6 Cognitive dysfunctions, 
strengths and limitations of this study
 ► The randomised, double-blind and placebo-con-
trolled design aims to determine outcome data (on 
the defined endpoints) and, thus, reduces the risk of 
bias, especially selection bias.
 ► Recruitment in routine care is expected to appropri-
ately reflect the patients and conditions in the two 
diagnostic groups.
 ► The performance of a controlled study demands the 
use of medical cannabidiol, and tetrahydrocannab-
inol instead of plant extracts, that is, tea or herbal 
preparations.
 ► There is no clinical evidence for the optimal dosage 
and application ranges. Thus, the treatment reg-
imens for the drugs used are an extrapolation of 
expert knowledge.
 ► Both primary and secondary endpoints are based on 
patient-reported outcome measurements and may 
be influenced by bias.
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such as concentration and memory problems, are also 
often reported in patients with chronic pain. These 
cognitive dysfunctions can be related to pain itself, sleep 
problems or reflect a side effect of the pharmacological 
treatment.4 6 RA affects the small joints of the hands and 
feet, but can also involve the larger joints.7 AS mainly 
affects the spinal and sacroiliac joints and is characterised 
by back pain and stiffness.8 Pain may involve nociceptive 
and non-nociceptive components and is based on the 
interaction between peripheral inflammation and central 
sensitisation.9 10 The immediate pain is triggered by the 
inflammation of the synovial tissue and/or consecutive 
oedema of the subchondral bone, and leads to a sensitisa-
tion of the peripheral nociceptors.11 
Thus, chronic pain is likely to be due to peripheral 
joint and central neuropathic pain mechanisms at various 
stages.11–16
Treatment of moderate to severe chronic pain is diffi-
cult to overcome, for several reasons: heterogeneity of 
the patients in a given diagnostic group, the progressive 
nature of the disease, involvement of multiple pain mech-
anisms and the presence of comorbidities, particularly 
in elderly patients.17 The rheumatologist is likely to pay 
full attention to the anti-inflammatory treatment. This 
approach implies the fact that chronic pain associated 
with increased mortality can be overlooked.18 19
There is a lack of knowledge about the effect of canna-
binoids in rheumatic diseases. Based on a Cochrane 
meta-analysis, the authors concluded that the existing 
clinical studies of c annabidiol (CBD) applied in mono-
therapy are of such poor quality that there is insufficient 
data to draw any conclusions about the effectiveness and/
or long-term security of the compound.20
Currently, only very few studies have investigated how 
medical cannabis affects cognitive functions, such as 
concentration and attention.21 A few studies have inves-
tigated the impact of illegally obtained cannabis in RA.20 
Furthermore, studies that have assessed medical cannabis 
did so mostly in the context of multiple sclerosis.20 22 23 In 
contrast to studies of recreational cannabis, the studies 
in persons with multiple sclerosis indicate that medical 
cannabis does not negatively affect cognition and could 
improve sleep quality. Given the limited data and the lack 
of a proper control condition, no definite conclusions of 
the potential cognitive impact of medical cannabis could 
be drawn.20 24
Hence, concerns about potential negative side effects 
of medical cannabis on cognition have led the Danish 
health authorities’ attention on a patient’s ability to drive 
safely.20 23 Furthermore, in the treatment of rheumatic 
diseases, there is no established routine nor rheumatolog-
ical competence to prescribe medical cannabis. Conse-
quently, there is considerable uncertainty and caution 
towards the use of medical cannabis, even in the North 
American countries, where it is already legal to prescribe 
these compounds for rheumatological conditions.23 24 
This can lead to patients resorting to self-medication with 
cannabinoids.20 24 25 Thus, there is a strong need for 
high-quality studies of the efficacy and side effects of 
cannabinoids.
The overall aim of the study is to investigate the effect 
of medical cannabis on pain in patients with RA and AS, 
to elaborate on the potential dosage of CBD and tetrahy-
drocannabinol (THC) and to explore if and how the test 
compounds affect patients’ cognitive functions and sleep.
MAtErIAls And MEthods
setting and study design
The study is an investigator-initiated, double-blinded, 
randomised, placebo-controlled intervention study of 
CBD, followed by an open label add-on of THC. It is 
designed to evaluate the efficacy and safety of medical 
cannabis, either as CBD or in the form of the combina-
tion treatment of CBD and THC as ‘add-on’ treatment 
for chronic pain in RA and AS. The patient-reported 
outcome measurement (PROM),26 a pain visual analogue 
scale (VAS) score27 at a value of at least 50 are the key 
inclusion criterion. The score range is from 0 to 100; a 
higher score indicates greater pain intensity. Thus, the 
null hypothesis, H0, is that receiving the active treatment 
with cannabis derivatives does not improve the pain situa-
tion in clinical assessment after 12, 24 and 36 weeks.
Clinical data and outcomes are registered in an elec-
tronic Case Report Form (eCRF), based on the Reuma-
eCRF system available within the Danish nationwide 
registry DANBIO.15 28 DANBIO contains actualised data 
on ongoing treatment regiments, which therefore easily 
can be monitored.
Biological samples are collected via the Danish Rheu-
matologic Biobank.29 Patients are recruited from four 
Danish university hospital departments. Patient inclusion 
is planned to start in November 2018 and is expected to 
continue for 14 months.
Participants
The study population consists of the following:
1. Patients with seropositive RA1 currently treated with 
either conventional disease modifying antirheumat-
ic drugs (cDMARDs) or biological disease modifying 
antirheumatic drugs (bDMARDs), and without clinical 
signs of arthritis, as assessed by a 40-swollen joint count.
2. Patients with AS, according to the modified New York 
criteria,2 currently receiving either non-steroidal an-
ti-inflammatory drugs (NSAIDs) and/or bDMARD, 
who show an absence of clinical signs of axial and 
peripheral arthritis and enthesitis, and who have an 
Ankylosing Spondylitis Disease Activity Score (ASDAS) 
<2.1.
Inclusion criteria
1. Minimum pain VAS 50, both at screening and inclusion.
2. Disease duration ≥2 years.
3. Ongoing treatment or earlier attempt to treat with 
paracetamol or NSAIDs without clinical signs of arthri-
tis or spondyloarthritis.
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4. Analgesic treatment unchanged at least 4 weeks before 
trial start.
Exclusion criteria
1. Age <18 years.
2. Pregnancy, pregnancy wish or ongoing breast feeding.
3. C-reactive protein (CRP) >10 mg/L.
4. Comorbidities, more specific competitive rheuma-
tological disorders, such as systemic lupus erythe-
matosus, scleroderma, polymyositis or chronic pain 
condition based on a further clinical detectable aeti-
ology (eg, fibromyalgia).
5. Evidence of serious uncontrolled concomitant cardio-
vascular, pneumological, neurological, endocrinolog-
ical, gastroenterological, urogenital, nephrological 
or hepatic impairment.
6. Major surgery performed <8 weeks before randomis-
ation or planned major surgical interventions.
7. Uncontrolled disease states, such as asthma, psoriasis 
or inflammatory bowel disease, where flares are com-
monly treated with oral or parenteral corticosteroids.
8. Evidence of active malignant disease, malignancies 
diagnosed or treated within the previous 2 years, 
including haematological malignancies and solid 
tumours.
9. Actual or previous harmful use of alcohol or drug 
abuse, in accordance with the WHO definition,30 
within the previous 2 years.
10. Ongoing treatment with opioids and/or cannabis 
products and/or neuroleptics, or treatment termi-
nated <4 weeks before inclusion.
11. Hypersensitivity to the study compounds.
12. Suspected for, or evidence of, active schizophrenia, 
other psychotic illness in the family history (first de-
gree relatives), other significant psychiatric disorder 
or treated depression associated with underlying 
condition.
13. Epilepsy or recurrent seizures.
14. Use of strong cytochrome P450 3A4 inducers.
Experimental treatment
The treatment starts with oral CBD 10 mg or placebo before 
bedtime, and increases after 2 weeks to 10 mg two times per 
day. Finally, and in case of lack of effect (VAS-pain reduction 
<20) from the beginning of the fifth week, the treatment 
increases to 10 mg three times per day.
The clinical assessment after 12 weeks defines how to 
proceed during the following 12 weeks: in case of a suffi-
cient response, that is, a VAS-pain reduction of ≥20, the 
established treatment continues randomised and without 
any further adjustment.
In case of insufficient response, that is, a VAS-pain reduc-
tion of <20, randomisation is terminated. Patients who 
received placebo are shifted to the active compound, that 
is, CBD treatment, and dose adjustment is performed, as 
mentioned above. In patients who received CBD treatment 
during the randomised period, the open label follow-up 
combines CBD with THC, that is, oral THC 2.5 mg daily is 
added to the ongoing CBD treatment.
The THC dose is increased after 2 weeks to 2.5 mg two 
times per day (in total, 5 mg THC/day), and in case of lack 
of effect (VAS-pain reduction <20, compared with VAS 20, as 
defined at clinical assessment after 12 weeks), after another 
2 weeks to 2.5 mg three times per day (in total, 7.5 mg THC/
day) from the beginning of the 17th week.
Figure 1 presents the consort flowchart and figure 2 the 
treatment flowchart.
randomisation procedure
Patients are stratified by diagnosis and by recruiting 
centre. Patients are randomly allocated to one of the two 
treatment arms—CBD or Placebo—by random permuted 
blocks. Randomisation is blinded to the treatment allo-
cation. Allocation is not known to anyone other than 
Glostrup Pharmacy, who produces and dispatches drug 
packages on request to each site. Sites receive a sealed, 
opaque envelope for each patient with the treatment 
allocation ready to be revealed, should this be required. 
Treatment is initiated within 2 weeks after randomis-
ation. Measurements of effect are carried out at base-
line before randomisation, and postintervention at 12, 
24 and 36 weeks postrandomisation. Data analysis and 
statistical programming are blinded. The randomisa-
tion procedure and data analysis are performed by an 
independent statistician at the Department of Regional 
Health Research (IRS), University of Southern Denmark, 
Gråsten, Denmark.
designated outcomes and clinical data
Primary outcome is the number of patients achieving an 
improvement of pain-VAS (Δ VAS-pain ≥20) after 12 
weeks of treatment.
Secondary outcomes
1. The fraction (%) of RA and AS patients that achieve 
an improvement in VAS-pain, as assessed by the reduc-
tion of Δ VAS ≥20 and outcome of the PainDETECT 
Questionnaire,10 31 after 24 and 36 weeks.
2. The fraction (%) of RA and AS patients that achieve 
an improved quality of life (QoL) situation, as assessed 
by Global-VAS with Δ VAS reduction ≥20 and by the 
Short Form (36) Health Survey (SF-36),32 after 24 and 
36 weeks.
3. The fraction (%) of AS patients that achieve a Bath An-
kylosing Spondylitis Disease Activity Index (BASDAI) 
<40 or reduction in BASDAI with Δ ≥20 after 12, 24 and 
36 weeks.33
4. A characterisation of AS and RA patients’ cogni-
tion and sleep quality, as assessed by the Trail Mak-
ing Test (TMT),34 the Digit Symbol Substitution Test 
(DSST)35 36 and the Pittsburgh Sleep Quality Index,37 
performed at baseline and after 12, 24 and 36 weeks.
5. A characterisation of the patients’ expectation for 
the treatment effect, as assessed by the Credibility/
Expectancy Questionnaire (CEQ) and by performing 
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semistructured interviews38–42 at baseline and after 12 
weeks.
6. A characterisation of and a final statement about seri-
ous adverse event (SAE) state.
7. The outcome measures include parameters recom-
mended by the Initiative on Methods, Measurement, 
and Pain Assessment in Clinical Trials (IMMPACT) 
paper.43
Clinical data
At baseline, and after 12, 24 and 36 weeks, respectively, 
data are collected in the DANBIO Reuma-eCRF system. 
Furthermore, two additional nurse consultations are 
performed after 4 and 16 weeks, to obtain safety infor-
mation and VAS-pain and to possibly perform a treat-
ment increase from the beginning of the 5th and/or 
17th week, respectively, as presented in the Experimental 
Figure 1 Presents the consort flowchart. TMT, Trail Making Test; VAS, visual analogue scale. 
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treatment section. The following data are collected at the 
time points as presented in figure 3.
1. Clinical measurements, that is, in RA the Disease 
Activity Score 28-joints (DAS28-CRP),44 45 Health 
Assessment Questionnaire and, in AS, the ASDAS 
and Bath Ankylosing Spondylitis scores for disease 
activity (BASDAI), function and measures are regis-
tered.46 47 In both patient groups, additional PROMs 
are obtained: VASs for pain, fatigue, patient’s global 
QoL score SF-36 and pain-score PainDETECT.10 31 
Furthermore, the effect of intervention on attention 
and concentration is investigated using the TMT and 
DSST.34–36 Additionally, sleep quality is evaluated with 
the Pittsburgh Sleep Quality Index.37 The expected ef-
fect of treatment is measured with the CEQ and semi-
structured interviews.
2. Exposures, that is, all concomitant treatment, especial-
ly current treatments with cDMARDs, bDMARDs and/
or analgesics, including dosing schedule and treat-
ment onset.
3. Comorbidities, for example, cardiovascular disease, di-
abetes and hypertension.
4. Lifestyle (blood pressure, exercise habits and smoking 
status).
5. Patient demographics, for example, diagnosis, age, 
gender, height, weight, body mass index, disease du-
ration, smoking status, educational level, marital sta-
tus, sick leave, occupation and ethnicity are obtained 
at baseline.
biological samples
Blood samples are obtained at baseline, and at 12, 24 
and 36 weeks. In addition to routine blood tests, blood 
samples are collected in one EDTA tube (9 mL), two 
serum tubes (2×9 mL) and one PAXgene blood RNA 
tube (2.5 mL, Becton & Dickinson, Lyngby, Denmark), as 
described previously.48 These are collected for definition 
Figure 2 Presents the treatment flowchart. CBD, cannabidiol; THC, tetrahydrocannabinol. 
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of drug concentration of CBD and THC, that is, moni-
toring of compliance, possible adverse events (AEs) and 
for further future analyses.
statistical analysis plan
The power calculation is based on the following assump-
tions for the primary outcome.
1. An expected proportion with a response of 50% or 
more in the CBD group and expected 20% in the pla-
cebo group (OR=4). Response is defined as a reduc-
tion in VAS-pain of at least 20 (range 0–100) after 12 
weeks of treatment.
2. A significance level of 0.05 in a two-sided z-test of pro-
portions.
3. A total of 180 patients will be included in two balanced 
groups, each consisting of 90 patients.
This setup gives a statistical power of 0.98 for the 
primary outcome. The power is reduced if the true differ-
ence between the groups is less than the expected 30 
percentage points, and if more than an expected 10% of 
the patients drop out of the experiment. Balanced groups 
of 45 patients will yield a power of 83% for two-group 
comparisons on binary outcomes, such as the primary 
Figure 3 The schedule of assessments and procedures. AE, adverse event; ASDAS, Ankylosing Spondylitis Disease Activity 
Score; BAS, Bath Ankylosing Spondylitis; BP, bloodpressure; CEQ, Credibility/Expectancy Questionnaire; DAS, Disease Activity 
Score; DSST, Digit Symbol Substitution Test; SAE, serious adverse event; TMT, Trail Making Test; VAS, visual analogue scale. 
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outcome. Slight deviations in sample sizes might occur 
because of block randomisation.
The primary outcome is tested by a z-test in a logistic 
regression model. The main parameter estimates the ratio 
of the odds of response for the intervention group relative 
to the control group. All tests are two-sided. Secondary 
outcomes are analysed using logistic and linear regres-
sion, depending on the data type. In the case of devia-
tions from the normality assumption, a non-parametric 
proportional odds model will be used. The secondary 
outcomes measured at baseline and postintervention, 
12, 24 and 36 weeks (follow-up) will be analysed using 
mixed-effects models, controlling for time of measure-
ment. The random-effects parameter is estimated for the 
clustering of repeated observations within patients. Anal-
ysis for the direct effects of CBD, THC and the interaction 
between those will be carried out separately, with placebo 
as the reference group for CBD.
Baseline measurements are reported as proportions of 
categorical variables, average and SD for normally distrib-
uted data, and median (range) scores for non-normal 
numerical data. All variables are reported for the two 
intervention groups. Baseline variables with a tendency 
(p<0.25) to coincide with the intervention group will be 
included as control variables in the test of the primary and 
secondary outcomes. The relationship between the tested 
variables at baseline and intervention allocation will be 
analysed with parametric (t-test) and non-parametric tests 
(χ2 and the Mann-Whitney test). Correction for multiple 
tests will be based on a gatekeeping model of access. This 
means that significant results for the secondary outcomes 
are interpreted solely as exploratory findings in case of a 
non-significant finding for the primary outcome.
Patient and public involvement
King Christian X’s Hospital for rheumatic diseases 
involves patients with inflammatory rheumatic diseases 
actively in both quality assurance projects, research proj-
ects and in the development of educational programmes. 
Furthermore, a user council was established in 2013 in 
the research department. The project is a consequence 
of rheumatic patient’s pain reality and the idea of the 
project was originally presented to the user council back in 
autumn 2017. Since then, two patients have been involved 
in the processing of the project. So far, the patient infor-
mation brochures have been developed based on the inte-
gration of the patient’s perspectives. PROMs, especially 
the patient’s pain VAS, are the main focus of the outcome 
measurements. Thus, both the burden and consequence 
of the intervention and the results of the given interven-
tion are transparent.
Meetings with the projects patient representatives will 
be arranged two times per year and the progress of the 
project is presented continuously for the user council.
Ethics and dissemination
All patients receive verbal and written information 
and give their written consent before enrolment, in 
accordance with Danish Ethics Committee guidelines. 
Online supplementary appendix 1 presents the projects 
consent statement in English. All patients are informed 
that they can withdraw from the study at any time. 
Although this would lead to the termination of project 
medication, patient withdrawal will have no consequences 
for regular course of treatment. In case of withdrawal, no 
subsequent patient-related registrations will be obtained.
The two cannabis derivatives used in this study are 
comparable to the authorised compounds in the drug 
Sativex, which is a registered drug in DenmarK.49 The 
patients will receive the information that efficacy of the 
applied test compound, as well as potential side effect 
may be comparable to Sativex. The patient’s rheumatolo-
gist will provide relevant project information in an outpa-
tient setting. Chronicity of the chosen diseases and the 
inclusion criteria implies the typical project patient to be 
well known with a serious burden of disease. Investigators 
and study nurses are specialists in the rheumatic field.
The treatment consists of CBD tablets and THC herbal 
capsule preparation, which are produced based on 
natural raw materials by Glostrup Pharmacy’s laboratory. 
The drugs are manufactured according to quality-en-
sured standardised procedures specifying the exact ingre-
dients in milligrams. This makes dosage and monitoring 
of the therapy safe according to Danish national Good 
Clinical Practice (GCP) guidelines. The side effects, are 
well known and well described.50 The study subjects are 
patients who are already associated to one of the four 
participating outpatient clinics. The blood samples at 
baseline, after 12 and 24 weeks, respectively, will be real-
ised in connection with routine blood tests, in accor-
dance with an a priori arranged outpatient visit and thus 
will not pose increased risks. At all visits, participants will 
asked about events and/or reactions. Based on this infor-
mation, the investigator will assess whether there is an AE, 
an adverse reaction, a SAE or a suspected unexpected 
serious adverse reaction. The GCP unit of the University 
of Southern Denmark monitors the study independently.
The patients will be contacted and informed regarding 
the overall study results if they indicate interest in this, 
and in accordance with the patient study consent form 
and as directed by the Danish Ethics Committee guide-
lines. The physician in charge of the project at each partic-
ipating outpatient clinic is responsible for conducting the 
study in accordance with the fifth edition of the Helsinki 
declaration. Study participation does not affect the estab-
lished anti-inflammatory treatment course of individual 
patients.
Results will be presented at international conferences 
and published in international and peer-reviewed medical 
journals. Negative, positive as well as inconclusive results 
will be published.
dIsCussIon And PotEntIAl lIMItAtIons
The project’s focus is on chronic pain, which cannot be 
attributed to inflammatory activity.
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Conventional and bDMARDs possess the potential to 
treat inflammation sufficiently. Thus, a treatment situa-
tion characterised by inflammatory disease activity should 
be treated according to the existing guidelines, that is, 
by adjusting the treatment to an adequate DMARD regi-
ment.1 2 Consequently, the absence of inflammation is a 
major inclusion criteria. Potential participants are well 
known as the study demands that their course of treat-
ment has taken place for at least 2 years. Thus, we assume 
that alcohol or drug abuse, as well as information about 
ongoing opioid and/or cannabis treatment are accessible 
information for the involved investigators. Furthermore, 
the demand of a disease duration of at least 2 years is 
supposed to ensure the presence of chronical pain.
CBD and THC are two of >80 active compounds in the 
marijuana plant.51
In contrast to THC, CBD does not exhibit a narcotic 
effect and/or intoxication.52 53 The biochemical effect of 
the cannabinoids is explained by the compounds’ inter-
action with specific receptors; the Cannabinoid receptor 
1 (CB-1) receptor is located on neurons and glial cells 
in different parts of the central nervous system, whereas 
the Cannabinoid receptor 2 (CB-2) receptor is found in 
structures of the immune system. The stimulating and 
narcotic effects of THC are considered to be caused by 
activation of CB-1 receptors. CBD has a very low affinity 
for these receptors.51 Thus, CBD binding to the CB-1 
receptors causes little to no narcotic effect. New studies 
show evidence that CBD affects autoimmune signalling 
pathways and that these mechanisms may be relevant to 
CBD’s therapeutic profile.52 53
The effect of CBD is studied in a placebo-controlled 
design, whereas the effect of a combination of CBD 
and THC is an open label continuation of the study. 
The scientifically ideal solution would have been a 
randomised study comparing both CBD, THC and 
placebo, for instance, in a cross-over design. Such a 
design would be characterised by the implicit risks of 
THC for all patients during the entire study period and 
it would require a significantly larger study. The actual 
design represents the balance between a wish to assess 
the effect of both CBD and THC correctly, while recog-
nising risks, including traffic safety issues, especially 
due to the THC treatment. Also, the possible negative 
effect on cognitive functioning can have a large impact 
on job functioning. Therefore, a more definite answer 
as to whether medical cannabis negatively affects cogni-
tion is important in relation to job functioning and 
autonomy. We feel our design will provide important 
information on THC, despite the design, and it has 
the advantage that we know when THC is applied, and 
thereby can take the necessary precautions.
The trial population is monitored regularly at the 
participating outpatient clinics and the individual 
longitudinal treatment is registered. DANBIO is the 
nationwide clinical quality database for rheuma-
tology.16 29 All adult patients treated with biological 
drugs are registered. Furthermore, patients with AS 
and RA are registered, regardless of treatment. Thus, 
the DANBIO based Reuma-eCRF system provides 
particularly good conditions for the collection and 
monitoring of validated data.
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